Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Hip Health and Mobility
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Rehabilitation Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. An inhaled drug cocktail could block COVID-19

An inhaled drug cocktail could block COVID-19

Stories Sep 17, 2020 3 minutes

The antibody-based treatment shows promise as temporary therapy against the virus.

The immunotherapy based on antibody research being developed by Vancouver Coastal Health Research Institute researcher Dr. Horacio Bach could provide short-term protection against the novel coronavirus, SARS-CoV-2. To date, COVID-19—a disease that largely affects the respiratory system—has claimed the lives of over 870,000 people worldwide. 

“One of the challenges we face with regards to a potential COVID-19 vaccine is that we do not know if it could offer long-term protection against reinfection,” says Bach. 

“Our system could offer an effective and safe therapy right away.”

Bach, study co-lead Dr. Ted Steiner and their team are developing single-chain antibodies that would neutralize proteins the COVID-19 virus employs to infiltrate cells—keys it uses to unlock cells in the body and destroy them. 

This is no small feat, as there are millions of potential antibodies to choose from. While it may seem like finding a needle in a haystack, Bach and his team have already identified over 20 hopefuls since beginning their research in April.

“We have some promising antibody candidates already, and one in particular that is neutralizing the virus.”

Researchers are using a novel approach involving a bacterial system to screen the antibodies. An antibody attached to a non-infectious virus is injected into a bacteria, and after a processing process, researchers check whether that blocks viral proteins used by COVID-19 to infiltrate host cells. 
 
Several protective antibodies against COVID-19 are being sought, as the virus possesses a multitude of protein keys to unlock the body’s cells. The ideal therapy would contain an antibody cocktail that can guard against multiple lines of viral attack. 

The therapy may be delivered via an inhaler, similar to Ventolin used for asthma, for short-term security from the virus. 

“The goal of this treatment is not to provide long-term immunity that a vaccine would,” says Bach, but one dose could shield against the virus for several hours or more until protective antibodies are processed and expelled from the body—long enough to catch a flight, go to an appointment or see a loved one.

Bach anticipates that this groundbreaking approach will enter human trials by spring 2021.

Inhaled antibodies could avoid a cytokine storm 

Bach’s therapy has the potential to prevent a cytokine storm—when the body’s immune system goes into overdrive and starts attacking healthy cells, which can lead to inflammation and organ failure. 

The novel coronavirus infects a certain type of cell, mostly primary airway epithelial cells. Once these cells are infected, white blood cell antibodies, called macrophages, attack the virus-containing cells and internalize them. 

Dr. Horacio Bach is an adjunct professor in the Division of Infectious Diseases at the University of British Columbia and manager of the Immunity and Infection Research Centre (IIRC) Proteomic and Antibody Engineering Facility.

Problematically, COVID-19 also infects macrophages with its protein key, which can lead to a heightened and potentially deadly immune response, or cytokine storm. “This is something that is unique to coronaviruses, as typically the macrophages would destroy the virus and not become infected with it,” says Bach.

Bach’s therapy could sidestep this problem by encapsulating COVID-19 with antibodies that would not infect macrophages, giving the body a leg up on slowing and stopping the disease. 

“We hope that this treatment will help the immune system clear the COVID-19 virus from the body without inducing inflammation or a cytokine storm.”

The safety of the therapy also increases the likelihood that it could be approved faster than other potential therapies, says Bach. 
 

Researchers

Horacio Bach

Related Articles

Heath care priority management post-COVID-19

COVID-19 linked to changes in the brain

Research shows lower dose drug strategy for severe COVID-19 patients both clinically and economically effective

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Immunity and Infection Research Centre

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Top Graduating Doctoral Student Award and Rising Star Award 2022 Recipients

Jun 28, 2022 award, trainee
Type
Stories

Cannabis legalization may have upped the number of older adults driving high

Jun 23, 2022 marijuana, senior, driving, men
Type
Stories

Heath care priority management post-COVID-19

Jun 17, 2022 COVID, patient engagement, health burden
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2022 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy